JP2009544618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544618A5 JP2009544618A5 JP2009520862A JP2009520862A JP2009544618A5 JP 2009544618 A5 JP2009544618 A5 JP 2009544618A5 JP 2009520862 A JP2009520862 A JP 2009520862A JP 2009520862 A JP2009520862 A JP 2009520862A JP 2009544618 A5 JP2009544618 A5 JP 2009544618A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aliphatic
- ring
- optionally substituted
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC(CC1=C(C(C2)C2C2)C=C*(*C(C(*)(C=*=C)N3C4=CC=C*(*)C=C4**C(*)(*)C3=O)=O)C=C1)*C1=C2C=CC=CC=CC=C1 Chemical compound CCC(CC1=C(C(C2)C2C2)C=C*(*C(C(*)(C=*=C)N3C4=CC=C*(*)C=C4**C(*)(*)C3=O)=O)C=C1)*C1=C2C=CC=CC=CC=C1 0.000 description 73
- YMQLSSLCXRWKQA-UHFFFAOYSA-O CC(C(N1)=O)(NC1=O)[IH+] Chemical compound CC(C(N1)=O)(NC1=O)[IH+] YMQLSSLCXRWKQA-UHFFFAOYSA-O 0.000 description 3
- SWFZYGSTUWMTPI-UHFFFAOYSA-N CC(C)(C=CN1)C1=O Chemical compound CC(C)(C=CN1)C1=O SWFZYGSTUWMTPI-UHFFFAOYSA-N 0.000 description 3
- BTJMCRAWBQGQIK-UHFFFAOYSA-N CC(C)(c(ccnc1)c1N1)C1=O Chemical compound CC(C)(c(ccnc1)c1N1)C1=O BTJMCRAWBQGQIK-UHFFFAOYSA-N 0.000 description 3
- FWWMMGOPZBVMNB-UHFFFAOYSA-N CC(C)(c(nccc1)c1N1)/C1=[O]\C Chemical compound CC(C)(c(nccc1)c1N1)/C1=[O]\C FWWMMGOPZBVMNB-UHFFFAOYSA-N 0.000 description 3
- CZGJOXNVXIVFAV-UHFFFAOYSA-N CC(C)(c(ncnc1)c1N1)/C1=[O]\C Chemical compound CC(C)(c(ncnc1)c1N1)/C1=[O]\C CZGJOXNVXIVFAV-UHFFFAOYSA-N 0.000 description 3
- OISPDNWOHCABMC-UHFFFAOYSA-N CC(C)C(C)(C1C(N2)OCCC1)C2=O Chemical compound CC(C)C(C)(C1C(N2)OCCC1)C2=O OISPDNWOHCABMC-UHFFFAOYSA-N 0.000 description 3
- SHAYFAIWNAOVSE-UHFFFAOYSA-N CC(C)C(C)(c1c(N2)nc[s]1)C2=O Chemical compound CC(C)C(C)(c1c(N2)nc[s]1)C2=O SHAYFAIWNAOVSE-UHFFFAOYSA-N 0.000 description 3
- QGECDFDEEKEVJO-UHFFFAOYSA-N CC(C)C(C)(c1cccnc1N1)C1=O Chemical compound CC(C)C(C)(c1cccnc1N1)C1=O QGECDFDEEKEVJO-UHFFFAOYSA-N 0.000 description 3
- SXVJIQFQZNOJAX-UHFFFAOYSA-N CC(C)C(CC(N1)=O)(C1=O)[IH]C Chemical compound CC(C)C(CC(N1)=O)(C1=O)[IH]C SXVJIQFQZNOJAX-UHFFFAOYSA-N 0.000 description 3
- WWFBWCVOVMKUCZ-UHFFFAOYSA-O CC(C1=C(N2)OCC1)(C2=O)[IH+] Chemical compound CC(C1=C(N2)OCC1)(C2=O)[IH+] WWFBWCVOVMKUCZ-UHFFFAOYSA-O 0.000 description 3
- FHDPJMNNOTUEKT-UHFFFAOYSA-N CC(C1=C(N2)OCCC1)(C2=O)[IH]I Chemical compound CC(C1=C(N2)OCCC1)(C2=O)[IH]I FHDPJMNNOTUEKT-UHFFFAOYSA-N 0.000 description 3
- LVQDZEAOMZKSMI-UHFFFAOYSA-N CC(C1=C(N2)SCC1)(C2=O)I Chemical compound CC(C1=C(N2)SCC1)(C2=O)I LVQDZEAOMZKSMI-UHFFFAOYSA-N 0.000 description 3
- OYOMJOLPSFPIBL-UHFFFAOYSA-N CC(C1C(N2)SCC1)(C2=O)[IH]C Chemical compound CC(C1C(N2)SCC1)(C2=O)[IH]C OYOMJOLPSFPIBL-UHFFFAOYSA-N 0.000 description 3
- DQFMPTUTAAIXAN-UHFFFAOYSA-N CC1(C)N=CNC1=O Chemical compound CC1(C)N=CNC1=O DQFMPTUTAAIXAN-UHFFFAOYSA-N 0.000 description 3
- CEDXQSMKYRXVHU-UHFFFAOYSA-N C[I-]C(c1c(N2)[s]cc1)(C2=O)[IH]C Chemical compound C[I-]C(c1c(N2)[s]cc1)(C2=O)[IH]C CEDXQSMKYRXVHU-UHFFFAOYSA-N 0.000 description 3
- DFIMFVQCVXMERG-UHFFFAOYSA-N O=C(C1([IH]I)[IH]I)Nc2c1cc[o]2 Chemical compound O=C(C1([IH]I)[IH]I)Nc2c1cc[o]2 DFIMFVQCVXMERG-UHFFFAOYSA-N 0.000 description 3
- BDEDPOLWMVWPSK-UHFFFAOYSA-N CC(C)(c1c(N2)nc[nH]1)C2=O Chemical compound CC(C)(c1c(N2)nc[nH]1)C2=O BDEDPOLWMVWPSK-UHFFFAOYSA-N 0.000 description 2
- FRUIAUUIOLTTEA-UHFFFAOYSA-N CC(C)(c1c(N2)nc[o]1)C2=O Chemical compound CC(C)(c1c(N2)nc[o]1)C2=O FRUIAUUIOLTTEA-UHFFFAOYSA-N 0.000 description 2
- FMYHJHHHIIJHRN-UHFFFAOYSA-N CC(C)C(C)(c(nccc1)c1N1)C1=O Chemical compound CC(C)C(C)(c(nccc1)c1N1)C1=O FMYHJHHHIIJHRN-UHFFFAOYSA-N 0.000 description 2
- NSEAPTQEZZLMKF-UHFFFAOYSA-N CC(C)C(CC(N1)=O)(C1=O)[I](C)I Chemical compound CC(C)C(CC(N1)=O)(C1=O)[I](C)I NSEAPTQEZZLMKF-UHFFFAOYSA-N 0.000 description 2
- RNWFHTNSACTMTG-UHFFFAOYSA-N CC(C)C1(C(C)I)N=CNC1=O Chemical compound CC(C)C1(C(C)I)N=CNC1=O RNWFHTNSACTMTG-UHFFFAOYSA-N 0.000 description 2
- CYKTWUBYWZXJSX-UHFFFAOYSA-N CC(C1=C(N2)SCCC1)(C2=O)[IH]I Chemical compound CC(C1=C(N2)SCCC1)(C2=O)[IH]I CYKTWUBYWZXJSX-UHFFFAOYSA-N 0.000 description 2
- VHNASZIROAFYSA-UHFFFAOYSA-O CC(C1C(N2)OCC1)(C2=O)[IH+](C)C Chemical compound CC(C1C(N2)OCC1)(C2=O)[IH+](C)C VHNASZIROAFYSA-UHFFFAOYSA-O 0.000 description 2
- LBHWSNRLSIZGPI-UHFFFAOYSA-N CC(C1C(N2)OCCC1)(C2=O)[IH]C Chemical compound CC(C1C(N2)OCCC1)(C2=O)[IH]C LBHWSNRLSIZGPI-UHFFFAOYSA-N 0.000 description 2
- VFJSJACITUAVID-UHFFFAOYSA-N CC(C=CN1)(C1=O)[IH]I Chemical compound CC(C=CN1)(C1=O)[IH]I VFJSJACITUAVID-UHFFFAOYSA-N 0.000 description 2
- IJUNQHFGBLBXBB-UHFFFAOYSA-N CC(c1c(N2)nn[nH]1)(C2=O)[I](C)C Chemical compound CC(c1c(N2)nn[nH]1)(C2=O)[I](C)C IJUNQHFGBLBXBB-UHFFFAOYSA-N 0.000 description 2
- BNMHGYUQURKKHB-UHFFFAOYSA-N C[IH]C1=[O][IH]c(ccnc2)c2N1 Chemical compound C[IH]C1=[O][IH]c(ccnc2)c2N1 BNMHGYUQURKKHB-UHFFFAOYSA-N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83239706P | 2006-07-21 | 2006-07-21 | |
| US60/832,397 | 2006-07-21 | ||
| PCT/US2007/016559 WO2008011190A1 (en) | 2006-07-21 | 2007-07-23 | Cgrp receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009544618A JP2009544618A (ja) | 2009-12-17 |
| JP2009544618A5 true JP2009544618A5 (https=) | 2011-08-18 |
| JP5511379B2 JP5511379B2 (ja) | 2014-06-04 |
Family
ID=38754729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009520862A Expired - Fee Related JP5511379B2 (ja) | 2006-07-21 | 2007-07-23 | Ｃｇｒｐレセプターアンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7842686B2 (https=) |
| EP (1) | EP2049532B1 (https=) |
| JP (1) | JP5511379B2 (https=) |
| CN (1) | CN101516875A (https=) |
| AT (1) | ATE469895T1 (https=) |
| AU (1) | AU2007275577A1 (https=) |
| CA (1) | CA2658573A1 (https=) |
| DE (1) | DE602007006961D1 (https=) |
| ES (1) | ES2343481T3 (https=) |
| WO (1) | WO2008011190A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY153249A (en) | 2005-11-14 | 2015-01-29 | Rinat Neuroscience Corp | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| CA2650932C (en) | 2006-05-09 | 2013-01-22 | Merck & Co., Inc. | Substituted spirocyclic cgrp receptor antagonists |
| US9056201B1 (en) | 2008-01-07 | 2015-06-16 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US10022558B1 (en) | 2008-01-07 | 2018-07-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| DK2227257T3 (da) | 2008-01-07 | 2013-09-30 | Salutaris Medical Devices Inc | Anordninger til minimal-invasiv ekstraokular afgivelse af stråling til den posteriore del af øjet |
| US9873001B2 (en) | 2008-01-07 | 2018-01-23 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive delivery of radiation to the eye |
| US8608632B1 (en) | 2009-07-03 | 2013-12-17 | Salutaris Medical Devices, Inc. | Methods and devices for minimally-invasive extraocular delivery of radiation and/or pharmaceutics to the posterior portion of the eye |
| US8602959B1 (en) | 2010-05-21 | 2013-12-10 | Robert Park | Methods and devices for delivery of radiation to the posterior portion of the eye |
| DK2265288T3 (en) | 2008-03-04 | 2016-06-06 | Labrys Biologics Inc | Methods for the treatment of inflammatory pain |
| CA2716424C (en) | 2008-03-04 | 2015-04-28 | Pfizer Limited | Methods of treating chronic pain |
| CA2715151A1 (en) * | 2008-03-28 | 2009-10-01 | Merck Sharp & Dohme Corp. | Monocyclic cgrp receptor antagonists |
| CA2735821A1 (en) * | 2008-09-08 | 2010-03-11 | Merck Sharp & Dohme Corp. | Monocyclic amide cgrp receptor antagonists |
| USD691269S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| USD691270S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to an eye |
| USD691268S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| USD691267S1 (en) | 2009-01-07 | 2013-10-08 | Salutaris Medical Devices, Inc. | Fixed-shape cannula for posterior delivery of radiation to eye |
| KR101519192B1 (ko) | 2009-08-28 | 2015-05-11 | 리나트 뉴로사이언스 코프. | 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법 |
| NZ717704A (en) | 2011-05-20 | 2022-08-26 | H Lundbeck As | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
| AU2012258980B8 (en) | 2011-05-20 | 2017-06-15 | H. Lundbeck A/S | Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| TWI685505B (zh) | 2011-05-20 | 2020-02-21 | 美商艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途 |
| CN104918945B (zh) | 2012-11-01 | 2018-01-05 | 因赛特公司 | 作为jak抑制剂的三环稠合噻吩衍生物 |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| CN103804367B (zh) * | 2014-02-28 | 2016-09-14 | 天津药物研究院 | 苯并氮杂卓衍生物、其制备方法和用途 |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| PE20161439A1 (es) | 2014-03-21 | 2017-01-26 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos |
| CN106687462A (zh) | 2014-04-30 | 2017-05-17 | 因赛特公司 | Jak1抑制剂的制备方法以及其新形式 |
| FR3030521B1 (fr) * | 2014-12-23 | 2019-07-26 | Galderma Research & Development | Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique |
| TWI763630B (zh) | 2015-07-02 | 2022-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
| MA44007A (fr) | 2016-02-05 | 2018-12-19 | Denali Therapeutics Inc | Inhibiteurs du récepteur interagissant avec protéine kinase 1 |
| USD815285S1 (en) | 2016-05-11 | 2018-04-10 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD814638S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD814637S1 (en) | 2016-05-11 | 2018-04-03 | Salutaris Medical Devices, Inc. | Brachytherapy device |
| USD808529S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| USD808528S1 (en) | 2016-08-31 | 2018-01-23 | Salutaris Medical Devices, Inc. | Holder for a brachytherapy device |
| WO2018055574A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
| EP3526219B1 (en) | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
| HRP20220636T1 (hr) | 2016-12-09 | 2022-07-22 | Denali Therapeutics Inc. | Spojevi korisni kao inhibitori ripk1 |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| MD3773593T2 (ro) | 2018-03-30 | 2024-10-31 | Incyte Corp | Tratament hidradenitei supurative utilizând inhibitori ai JAK |
| WO2019204537A1 (en) | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| CN113227140A (zh) | 2019-01-08 | 2021-08-06 | H.隆德贝克有限公司 | 使用抗cgrp抗体急性治疗和快速治疗头痛 |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| IL314082A (en) | 2022-01-12 | 2024-09-01 | Denali Therapeutics Inc | Crystal forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazapin-3-yl)- H4- 1,2,4-triazole-3-carboxamide |
| US20250084044A1 (en) * | 2022-01-14 | 2025-03-13 | Enko Chem, Inc. | Protoporphyrinogen oxidase inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7205293B2 (en) * | 2003-03-14 | 2007-04-17 | Merck & Co., Inc. | Benodiazepine spirohydantoin CGRP receptor antagonists |
| CA2519475A1 (en) * | 2003-03-14 | 2004-09-30 | Merck & Co., Inc. | Bicyclic anilide spirohydantoin cgrp receptor antagonists |
| CA2518830A1 (en) * | 2003-03-14 | 2004-09-30 | Merck & Co., Inc. | Carboxamide spirohydantoin cgrp receptor antagonists |
| AU2004221891B2 (en) * | 2003-03-14 | 2009-11-19 | Merck Sharp & Dohme Corp. | Monocyclic anilide spirohydantoin CGRP receptor antagonists |
| JP4673296B2 (ja) * | 2003-03-14 | 2011-04-20 | メルク・シャープ・エンド・ドーム・コーポレイション | アリールスピロヒダントインｃｇｒｐ受容体拮抗物質 |
| ATE518852T1 (de) * | 2004-09-13 | 2011-08-15 | Merck Sharp & Dohme | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten |
| US7390798B2 (en) * | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| CA2579847A1 (en) * | 2004-09-13 | 2006-03-23 | Merck & Co., Inc. | Bicyclic anilide spirolactam cgrp receptor antagonists |
| CA2582593A1 (en) * | 2004-10-07 | 2006-04-20 | Merck & Co., Inc. | Cgrp receptor antagonists |
| US7384930B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
-
2007
- 2007-07-23 JP JP2009520862A patent/JP5511379B2/ja not_active Expired - Fee Related
- 2007-07-23 EP EP07796984A patent/EP2049532B1/en not_active Not-in-force
- 2007-07-23 AU AU2007275577A patent/AU2007275577A1/en not_active Abandoned
- 2007-07-23 CN CNA2007800342187A patent/CN101516875A/zh active Pending
- 2007-07-23 CA CA002658573A patent/CA2658573A1/en not_active Abandoned
- 2007-07-23 DE DE602007006961T patent/DE602007006961D1/de active Active
- 2007-07-23 WO PCT/US2007/016559 patent/WO2008011190A1/en not_active Ceased
- 2007-07-23 ES ES07796984T patent/ES2343481T3/es active Active
- 2007-07-23 AT AT07796984T patent/ATE469895T1/de not_active IP Right Cessation
-
2009
- 2009-01-21 US US12/356,745 patent/US7842686B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544618A5 (https=) | ||
| JP7664947B2 (ja) | Ｉｌ－１７の調節因子としてのイミダゾリダジン | |
| AU2018236691B2 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| US20220380338A1 (en) | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors | |
| JP7331843B2 (ja) | Ｂｔｋ阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および／または治療剤 | |
| CA3121719A1 (en) | Amino-acid anilides as small molecule modulators of il-17 | |
| JP2021534124A5 (https=) | ||
| JP2016516043A5 (https=) | ||
| JP2011523412A5 (https=) | ||
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| BR112020008850A2 (pt) | composto, composição farmacêutica e método para tratar uma doença mediada por jak1 e jak3 | |
| CA3075669A1 (en) | Bisamide sarcomere activating compounds and uses thereof | |
| TW200305425A (en) | 8-Azaprostaglandin derivatives and medicament containing same as active ingredient | |
| RU2020121152A (ru) | Твердые формы ингибитора калликреина плазмы и их соли | |
| JP7721142B2 (ja) | Ｍａｓｐ－２阻害剤および使用方法 | |
| UA128085C2 (uk) | ТРЕТИННІ СПИРТИ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font> | |
| UA128288C2 (uk) | СПОЛУКИ АМІНОПІРАЗИНДІОЛУ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font> | |
| JP2017538753A5 (https=) | ||
| JP2024160326A (ja) | Ｅａａｔ２活性化因子およびその使用方法 | |
| KR20110044947A (ko) | 과잉활성 면역계 치료를 위한 사이클로리그난의 용도 | |
| EP4341254A1 (en) | Inhibitors and degraders of pip4k protein | |
| RU2018101473A (ru) | Депо-препарат, содержащий сложный эфир лимонной кислоты | |
| RU2013136895A (ru) | Новое бициклическое соединение или его соль | |
| JP2015502371A5 (https=) | ||
| CA3233410A1 (en) | Benzimidazoles as modulators of il-17 |